Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RALDESY vs AMRIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective beta-3 adrenergic receptor agonist; relaxes detrusor smooth muscle during storage phase of urinary bladder fill cycle, increasing bladder capacity and reducing urgency.
Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.
Overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency
Treatment of spasticity due to multiple sclerosis, spinal cord injury, or other spinal cord disorders
Intravenous: 1 mg/kg every 8 hours; maximum single dose 100 mg.
15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.
4-6 hours in adults; prolonged to 8-12 hours in elderly or renal impairment (Cr Cl <30 m L/min)
Terminal elimination half-life approximately 32 hours (range 28–40 hours); clinically relevant for once-daily dosing in chronic muscle spasm
Extensively metabolized by multiple enzymes including CYP2D6, CYP3A4, butyrylcholinesterase, and UDP-glucuronosyltransferases (UGTs).
Hepatic via deamination; primarily metabolized by monoamine oxidase B (MAO-B) to inactive metabolites.
Primarily renal (85-90%) with 60% unchanged; biliary/fecal (10-15%)
Renal: approximately 40% as unchanged drug and metabolites; biliary/fecal: minimal; total clearance: 2.5 L/min
99% bound primarily to albumin
40–45% bound to serum proteins, primarily albumin
0.15-0.25 L/kg, indicating limited extravascular distribution
5–8 L/kg; suggests extensive tissue distribution, including skeletal muscle
Oral: 85-90%
Oral: 85–95% (extended-release formulation)
GFR ≥60 m L/min: no adjustment. GFR 30-59 m L/min: 1 mg/kg every 12 hours. GFR <30 m L/min: 1 mg/kg every 24 hours. Hemodialysis: administer after dialysis.
No specific dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min).
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: not recommended.
Contraindicated in Child-Pugh class C. For Child-Pugh class A or B: initiate at 15 mg once daily; do not increase dose. Use with caution.
Children 1 month to 12 years: 1.5 mg/kg IV every 8 hours (max 100 mg per dose). Children ≥12 years: same as adult dosing.
Safety and efficacy not established in pediatric patients under 12 years. For ages 12 and older, same as adult dosing.
No specific age-based adjustment; use caution due to age-related renal decline; follow renal function-based dosing.
Initiate at 15 mg once daily. Due to higher incidence of anticholinergic effects and falls, monitor closely; consider lower doses in frail elderly.
Not applicable.
None
May cause urinary retention, especially in patients with bladder outlet obstruction or taking anticholinergic medications.,Avoid use in patients with severe uncontrolled hypertension (systolic >180 mm Hg or diastolic >110 mm Hg).,Angioedema reported; discontinue if occurs.,Use with caution in patients with hepatic impairment (Child-Pugh class C: not recommended).
Abrupt discontinuation may precipitate withdrawal syndrome including hallucinations, seizures, autonomic instability.,May cause sedation, dizziness, and muscle weakness; caution with activities requiring alertness.,Use with caution in patients with impaired renal function due to reduced clearance.,May exacerbate seizures in patients with epilepsy.,Avoid concomitant use with other CNS depressants.
Hypersensitivity to mirabegron or any excipient.,Severe uncontrolled hypertension.
Hypersensitivity to amrix or baclofen.,Abrupt withdrawal is contraindicated; must be tapered.,Concomitant use with MAO inhibitors is contraindicated due to risk of hypertensive crisis.
Avoid tyramine-rich foods: aged cheeses (e.g., cheddar, blue cheese), cured/smoked meats (e.g., salami, pepperoni), fermented foods (e.g., sauerkraut, soy sauce), draft beers, red wine, and overripe fruits. These can cause a hypertensive crisis when combined with MAO-B inhibitors.
Avoid grapefruit and grapefruit juice during treatment as they may increase cyclobenzaprine levels. Taking AMRIX with or without food does not significantly affect absorption. Alcohol should be strictly avoided as it potentiates CNS depression.
FDA Pregnancy Category D. First trimester: known teratogen causing craniofacial defects, neural tube defects, and cardiovascular malformations. Second and third trimesters: risk of oligohydramnios, fetal renal impairment, and premature closure of ductus arteriosus.
Cyclobenzaprine (AMRIX) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate well-controlled studies in pregnant women are lacking. Use only if clearly needed. First trimester: no specific teratogenic effects documented; second and third trimesters: avoid near term due to potential neonatal effects (e.g., sedation, withdrawal).
Contraindicated during breastfeeding. M/P ratio unknown; drug is excreted in human milk and may cause severe adverse effects in nursing infants.
Cyclobenzaprine is excreted into human milk in small amounts. M/P ratio: not established. Use with caution in nursing mothers; monitor infant for sedation, poor feeding, or hypotonia.
Due to increased plasma volume and renal clearance in pregnancy, higher doses may be required. Start at lower end of therapeutic range and titrate based on response. Avoid in third trimester due to risk of fetal harm; consider alternative therapy.
No specific dose adjustments are recommended based on pharmacokinetic changes in pregnancy; however, due to potential for increased clearance, lowest effective dose should be used. Avoid use during labor and delivery due to potential neonatal depression.
RALDESY is a brand name for rasagiline, an MAO-B inhibitor used for Parkinson's disease. Avoid concurrent use with MAO-A inhibitors or serotonergic drugs due to risk of serotonin syndrome. Monitor for hypertension, especially when consuming tyramine-rich foods. Start at 1 mg once daily; can increase to 2 mg in patients not responding. Do not use with opioids (e.g., meperidine, tramadol) or St. John's wort.
AMRIX (cyclobenzaprine extended-release) should not be used longer than 2-3 weeks due to lack of evidence for efficacy in muscle spasm beyond that period. It has significant anticholinergic effects; avoid in patients with glaucoma, urinary retention, or those taking MAOIs. Do not crush or chew capsules; administer once daily at same time. Onset of action is delayed compared to immediate-release cyclobenzaprine.
Take RALDESY at the same time each day with or without food.,Avoid foods high in tyramine (e.g., aged cheeses, cured meats, fermented products) to prevent hypertensive crisis.,Do not stop taking RALDESY abruptly; consult your doctor before discontinuing.,Report symptoms like severe headache, palpitations, or confusion immediately.,Inform all healthcare providers you are taking RALDESY, especially before surgery or starting new medications.
Take AMRIX exactly once daily at the same time each day; do not crush, chew, or open the capsule.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase the risk of severe drowsiness and dizziness.,Do not drive or operate heavy machinery until you know how AMRIX affects you; it may cause drowsiness, dizziness, or blurred vision.,Contact your healthcare provider if you experience symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness, nausea, diarrhea).,Do not use AMRIX for longer than 2-3 weeks unless specifically directed by your doctor; prolonged use is not recommended.,Inform your doctor if you have a history of urinary retention, glaucoma, thyroid disorders, heart problems, or liver disease.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double the dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RALDESY vs AMRIX, answered by our medical review team.
RALDESY is a Muscle Relaxant that works by Selective beta-3 adrenergic receptor agonist; relaxes detrusor smooth muscle during storage phase of urinary bladder fill cycle, increasing bladder capacity and reducing urgency.. AMRIX is a Muscle Relaxant that works by Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RALDESY and AMRIX depend on the specific clinical indication. These are both Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RALDESY is: Intravenous: 1 mg/kg every 8 hours; maximum single dose 100 mg.. The standard adult dose of AMRIX is: 15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RALDESY and AMRIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RALDESY is classified as Category C. FDA Pregnancy Category D. First trimester: known teratogen causing craniofacial defects, neural tube defects, and cardiovascular malformations. Second and third trimesters: risk of. AMRIX is classified as Category C. Cyclobenzaprine (AMRIX) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate well-controlled studies in pregnant women are lacki. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.